BioSpace News Archive

Only days after announcing a COVID-19 vaccine production deal with the UK government, New York-based Pfizer and Germany-based BioNTech signed an even bigger deal with the U.S. government.

How long do antibodies against SARS-CoV-2, the novel coronavirus that causes the disease, last? And if they are gone, is your immune system still able to offer protection against getting infected again?

San Francisco-based Olema Oncology secured $54 million in an oversubscribed Series B financing round to support the development of its lead breast cancer treatment, as well as expand its ongoing research and development programs.

The U.S. Food and Drug Administration (FDA) approved Xywav, the first new treatment option indicated for both cataplexy and excessive daytime sleepiness in people living with narcolepsy in more than 15 years.

Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

AbbVie announced that its Rinvoq (upadacitinib) as a monotherapy hit both primary and all secondary endpoints in the second Phase III trial, Measure Up 2, in patients with moderate to severe atopic dermatitis.

Two Chinese nationals have been indicted for hacking into the computer systems of hundreds of companies, governments, non-governmental organizations and more to steal trade secrets, including data on treatments related to COVID-19.

According to the report, the options are worth $101 million and do not hinge on the clinical success of the vaccine program.

Locanabio combines gene therapy with RNA modification for a novel, highly flexible platform that can modify, replace or eliminate dysfunctional RNA. Gene therapy and RNA modification have each been used before. It’s the combination that makes it unique.

Noah Gottdiener of Duff & Phelps and Thierry Porté of J.C. Flowers & Co. join BOD Retired Eli Lilly executive Joseph B. Kelley joins Business Advisory Board BOSTON, July 22, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc. , a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the appointment of three prominent business leaders to its Board of Directors and Business Advisory Board: Noah Gottdiener, Chief Executive Officer an